Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antibody-Drug Conjugates: The Next Generation Of Moving Parts

This article was originally published in Start Up

Executive Summary

The next generation of antibody-drug conjugates have much room for improvement: engineered proteins, drugs, the linkers that bond them together, and perhaps even new targets to attack. All their complexity is an invitation to innovation, but will the parts come together into products that prove safe and efficacious in the clinic?

Advertisement

Related Content

Your First Drug's Approved and Launched...Now What?
ImmunoGen Wants A Bigger Share Of The Antibody-Drug Conjugate Pie
Back To School: Big Pharmas Test New Models For Tapping Academia
Making The Case For Antibody-Drug Conjugates
With Novartis, ImmunoGen Adds $45 Mil. And Another Licensor For Its Antibody-Drug Conjugate Platform

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC092216

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel